ArticleCureus2025
Managing Levothyroxine Malabsorption in Refractory Hypothyroidism: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levothyroxine malabsorption is a rare but important cause of refractory hypothyroidism that necessitates alternative therapeutic approaches. We present the case of a 55-year-old woman with long-standing hypothyroidism who continued to experience persistent symptoms despite being on high-dose oral levothyroxine (1500 mcg daily). Laboratory investigations revealed an elevated thyroid-stimulating hormone (TSH) level of 14.160 mIU/L, along with positive anti-gliadin and anti-parietal cell antibodies. A supervised thyroxine (T4) absorption test confirmed true levothyroxine malabsorption. The patient was subsequently transitioned to a liquid levothyroxine formulation at a reduced dose of 600 mcg, which led to significant clinical improvement and normalization of thyroid function. Levothyroxine malabsorption can be attributed to underlying gastrointestinal conditions such as celiac disease and atrophic gastritis. The T4 malabsorption test is a valuable tool in distinguishing true malabsorption from non-adherence or pseudo-malabsorption. In cases of confirmed malabsorption, liquid or parenteral formulations may help improve absorption and lead to better clinical outcomes. This case highlights the importance of identifying thyroid hormone malabsorption in patients with refractory hypothyroidism to ensure optimal management and therapeutic success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.